#POS0263 #EULAR2022 In #rituximab-treated RMD patients with undetectable humoral response to primary #COVID 💉, a study (N=84) found Re-Vaccination with mRNA (2 shots) was better than a Booster (1 shot). Lend support for current approach: 2 + 3rd Primary + Booster @RheumNow https://t.co/AH0wpVKbHc

NORD-STAR substudy looking at anticoagulant effects. Important as RA assoc. ⬆️DVT/PE. DMARDs improve haemostatic imbalance, with bDMARDs stronger effect than csDMARD (may relate to better disease control with this) @RheumNow #EULAR2022 OP0059 https://t.co/TKwAZMOZjY https://t.co/IazrfD7z7k

• EULAR Abstract Archive

After the #EULAR2022 Recommendations session, it begs the question - Do we follow it? In Germany, the answer is sometimes Early bDMARD or JAKi is more frequent in recent years. 1/3 of patients did not receive recommended treatment escalation after 1st csDMARD POS0234 @Rheumnow https://t.co/0DaP5b7Htc